Intercept Pharmaceuticals Inc (ICPT) EVP Sells $152,806.54 in Stock

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) EVP Christian Weyer sold 1,343 shares of the stock in a transaction on Thursday, November 29th. The shares were sold at an average price of $113.78, for a total value of $152,806.54. Following the completion of the transaction, the executive vice president now owns 17,162 shares of the company’s stock, valued at approximately $1,952,692.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

NASDAQ ICPT traded down $3.92 during trading on Thursday, reaching $110.14. 393,668 shares of the company’s stock were exchanged, compared to its average volume of 660,995. Intercept Pharmaceuticals Inc has a fifty-two week low of $51.05 and a fifty-two week high of $133.74. The firm has a market capitalization of $3.22 billion, a PE ratio of -7.66 and a beta of -1.08. The company has a current ratio of 5.98, a quick ratio of 5.98 and a debt-to-equity ratio of 3.83.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Wednesday, October 31st. The biopharmaceutical company reported ($2.18) EPS for the quarter, topping the Zacks’ consensus estimate of ($2.65) by $0.47. Intercept Pharmaceuticals had a negative return on equity of 645.54% and a negative net margin of 202.93%. The firm had revenue of $47.00 million during the quarter, compared to analyst estimates of $48.24 million. During the same period last year, the company posted ($2.89) EPS. The business’s quarterly revenue was up 13.8% compared to the same quarter last year. Research analysts anticipate that Intercept Pharmaceuticals Inc will post -10.35 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in ICPT. FMR LLC boosted its position in Intercept Pharmaceuticals by 17.5% during the 2nd quarter. FMR LLC now owns 4,437,332 shares of the biopharmaceutical company’s stock worth $372,336,000 after acquiring an additional 661,542 shares during the period. First Trust Advisors LP boosted its position in Intercept Pharmaceuticals by 29.9% during the 3rd quarter. First Trust Advisors LP now owns 1,092,319 shares of the biopharmaceutical company’s stock worth $138,025,000 after acquiring an additional 251,735 shares during the period. Northern Trust Corp boosted its position in Intercept Pharmaceuticals by 190.3% during the 2nd quarter. Northern Trust Corp now owns 257,755 shares of the biopharmaceutical company’s stock worth $21,629,000 after acquiring an additional 168,955 shares during the period. Deutsche Bank AG boosted its position in Intercept Pharmaceuticals by 24.9% during the 3rd quarter. Deutsche Bank AG now owns 438,720 shares of the biopharmaceutical company’s stock worth $55,435,000 after acquiring an additional 87,473 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its position in Intercept Pharmaceuticals by 104.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 110,805 shares of the biopharmaceutical company’s stock worth $9,298,000 after acquiring an additional 56,556 shares during the period. Hedge funds and other institutional investors own 63.20% of the company’s stock.

A number of research firms recently weighed in on ICPT. Needham & Company LLC reiterated a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Thursday, August 2nd. Wedbush reiterated a “buy” rating and issued a $203.00 price target (down previously from $217.00) on shares of Intercept Pharmaceuticals in a research report on Friday, August 3rd. BidaskClub lowered Intercept Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 22nd. ValuEngine upgraded Intercept Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 2nd. Finally, Royal Bank of Canada reiterated a “buy” rating and issued a $115.00 price target on shares of Intercept Pharmaceuticals in a research report on Friday, August 3rd. Seven equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $148.25.

TRADEMARK VIOLATION NOTICE: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2018/11/29/intercept-pharmaceuticals-inc-icpt-evp-sells-152806-54-in-stock.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

See Also: Derivative

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply